{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:34:44Z","timestamp":1791588884024,"version":"4.3.4"},"reference-count":25,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.1248\/bpb.b25-00095","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T22:10:08Z","timestamp":1752531008000},"page":"1016-1021","source":"Crossref","is-referenced-by-count":3,"title":["FLG249 Exhibits FXR Antagonist Activity by Inducing Dissociation of Both Corepressors and Coactivators from FXR"],"prefix":"10.1248","volume":"48","author":[{"given":"Yusuke","family":"Iguchi","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Gohda","sequence":"additional","affiliation":[{"name":"Computer-Aided Molecular Modeling Research Center, Kansai (CAMM-Kansai), Nishinomiya, Hyogo 663\u20138241, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Fujimori","sequence":"additional","affiliation":[{"name":"Department of Pathobiochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569\u20131094, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Sera","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneo","family":"Imanaka","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"},{"name":"Graduate School of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Une","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"},{"name":"Graduate School of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Teno","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"},{"name":"Faculty of Clinical Nutrition, Hiroshima International University, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. <i>Science<\/i>, <b>284<\/b>, 1362\u20131365 (1999).","DOI":"10.1126\/science.284.5418.1362"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. <i>Science<\/i>, <b>284<\/b>, 1365\u20131368 (1999).","DOI":"10.1126\/science.284.5418.1365"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Han CY. Update on FXR biology: promising therapeutic target? <i>Int. J. Mol. Sci.<\/i>, <b>19<\/b>, 2069  (2018).","DOI":"10.3390\/ijms19072069"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Jiang L, Zhang H, Xiao D, Wei H, Chen Y. Farnesoid X receptor (FXR): structures and ligands. <i>Comput. Struct. Biotechnol. J.<\/i>, <b>19<\/b>, 2148\u20132159 (2021).","DOI":"10.1016\/j.csbj.2021.04.029"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Panzitt K, Zollner G, Marschall HU, Wagner M. Recent advances on FXR-targeting therapeutics. <i>Mol. Cell. Endocrinol.<\/i>, <b>552<\/b>, 111678 (2022).","DOI":"10.1016\/j.mce.2022.111678"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Jin L, Feng X, Rong H, Pan Z, Inaba Y, Qiu L, Zheng W, Lin S, Wang R, Wang Z, Wang S, Liu H, Li S, Xie W, Li Y. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. <i>Nat. Commun.<\/i>, <b>4<\/b>, 1937 (2013).","DOI":"10.1038\/ncomms2924"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Amano Y, Shimada M, Miura S, Adachi R, Tozawa R. Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates. <i>Eur. J. Pharmacol.<\/i>, <b>723<\/b>, 108\u2013115 (2014).","DOI":"10.1016\/j.ejphar.2013.10.048"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Teno N, Iguchi Y, Oda K, Yamashita Y, Masuda A, Fujimori K, Une M, Gohda K. Discovery of orally active and nonsteroidal farnesoid X receptor (FXR) antagonist with propensity for accumulation and responsiveness in ileum. <i>ACS Med. Chem. Lett.<\/i>, <b>12<\/b>, 420\u2013425 (2021).","DOI":"10.1021\/acsmedchemlett.0c00640"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Iguchi Y, Yamashita Y, Gohda K, Oda K, Fujimori K, Sera Y, Imanaka T, Yamaguchi M, Une M, Teno N. FXR antagonist FLG249 lowers hepatic triacylglycerol and serum cholesterol level in high-fat diet-induced obese mice. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 1429\u20131436 (2024).","DOI":"10.1248\/bpb.b24-00311"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Teno N, Iguchi Y, Yamashita Y, Mori N, Une M, Nishimaki-Mogami T, Gohda K. Discovery and optimization of benzimidazole derivatives as a novel chemotype of farnesoid X receptor (FXR) antagonists. <i>Bioorg. Med. Chem.<\/i>, <b>25<\/b>, 1787\u20131794 (2017).","DOI":"10.1016\/j.bmc.2017.01.040"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Teno N, Yamashita Y, Iguchi Y, Fujimori K, Une M, Nishimaki-Mogami T, Hiramoto T, Gohda K. Nonacidic chemotype possessing <i>N<\/i>-acylated piperidine moiety as potent farnesoid X receptor (FXR) antagonists. <i>ACS Med. Chem. Lett.<\/i>, <b>9<\/b>, 78\u201383 (2018).","DOI":"10.1021\/acsmedchemlett.7b00363"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Teno N, Yamashita Y, Masuda A, Iguchi Y, Oda K, Fujimori K, Hiramoto T, Nishimaki-Mogami T, Une M, Gohda K. Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: Comprehensive understanding of structure-activity relationship of FXR antagonists. <i>Bioorg. Med. Chem.<\/i>, <b>27<\/b>, 2220\u20132227 (2019).","DOI":"10.1016\/j.bmc.2019.04.029"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) McKenna NJ, Lanz RB, O\u2019Malley BW. Nuclear receptor coregulators: cellular and molecular biology. <i>Endocr. Rev.<\/i>, <b>20<\/b>, 321\u2013344 (1999).","DOI":"10.1210\/edrv.20.3.0366"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Lonard DM, O\u2019Malley BW. Nuclear receptor coregulators: modulators of pathology and therapeutic targets. <i>Nat. Rev. Endocrinol.<\/i>, <b>8<\/b>, 598\u2013604 (2012).","DOI":"10.1038\/nrendo.2012.100"},{"key":"15","unstructured":"15) Wong MM, Guo C, Zhang J. Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation. <i>Am. J. Clin. Exp. Urol.<\/i>, <b>2<\/b>, 169\u2013187 (2014)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kojetin DJ, Burris TP. Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. <i>Mol. Pharmacol.<\/i>, <b>83<\/b>, 1\u20138 (2013).","DOI":"10.1124\/mol.112.079285"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kainuma M, Makishima M, Hashimoto Y, Miyachi H. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. <i>Bioorg. Med. Chem.<\/i>, <b>15<\/b>, 2587\u20132600 (2007).","DOI":"10.1016\/j.bmc.2007.01.046"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Germain P, Gaudon C, Pogenberg V, Sanglier S, Van Dorsselaer A, Royer CA, Lazar MA, Bourguet W, Gronemeyer H. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. <i>Chem. Biol.<\/i>, <b>16<\/b>, 479\u2013489 (2009).","DOI":"10.1016\/j.chembiol.2009.03.008"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kang H, Ye MB, Bahk YY. Expression and purification of human farnesoid X receptor-ligand binding domain as soluble form using a dual cistronic expression vector. <i>J. Microbiol. Biotechnol.<\/i>, <b>23<\/b>, 322\u2013328 (2013).","DOI":"10.4014\/jmb.1212.12014"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Webb P, Anderson CM, Valentine C, Nguyen P, Marimuthu A, West BL, Baxter JD, Kushner PJ. The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I\/LXXII) that serve as receptor interaction domains (IDs). <i>Mol. Endocrinol.<\/i>, <b>14<\/b>, 1976\u20131985 (2000).","DOI":"10.1210\/mend.14.12.0566"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Eberhardt J, McEwen AG, Bourguet W, Moras D, Dejaegere A. A revisited version of the apo structure of the ligand-binding domain of the human nuclear receptor retinoic X receptor <i>\u03b1<\/i>. <i>Acta Crystallogr. F Struct. Biol. Commun.<\/i>, <b>75<\/b>, 98\u2013104 (2019).","DOI":"10.1107\/S2053230X18018022"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. <i>Nat. Struct. Biol.<\/i>, <b>3<\/b>,  87\u201394 (1996).","DOI":"10.1038\/nsb0196-87"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Chrisman IM, Nemetchek MD, de Vera IMS, Shang J, Heidari Z, Long Y, Reyes-Caballero H, Galindo-Murillo R, Cheatham TE 3rd, Blayo AL, Shin Y, Fuhrmann J, Griffin PR, Kamenecka TM, Kojetin DJ, Hughes TS. Defining a conformational ensemble that directs activation of PPAR\u03b3. <i>Nat. Commun.<\/i>, <b>9<\/b>, 1794 (2018).","DOI":"10.1038\/s41467-018-04176-x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Heidari Z, Chrisman IM, Nemetchek MD, Novick SJ, Blayo AL, Patton T, Mendes DE, Diaz P, Kamenecka TM, Griffin PR, Hughes TS. Definition of functionally and structurally distinct repressive states in the nuclear receptor PPAR\u03b3. <i>Nat. Commun.<\/i>, <b>10<\/b>, 5825 (2019).","DOI":"10.1038\/s41467-019-13768-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Hsia EY, Goodson ML, Zou JX, Privalsky ML, Chen HW. Nuclear receptor coregulators as a new paradigm for therapeutic targeting. <i>Adv. Drug Deliv. Rev.<\/i>, <b>62<\/b>, 1227\u20131237 (2010).","DOI":"10.1016\/j.addr.2010.09.016"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00095\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T04:03:52Z","timestamp":1752897832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00095\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00095","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"article-number":"b25-00095"}}